A Phase 2, Single Blind, Single Center, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine +/- OMV, When Administered to Healthy Infants 6-8 Months Old.
Latest Information Update: 29 Jul 2019
At a glance
- Drugs Meningococcal vaccine group B (Primary) ; Meningococcal vaccine group B OMV Novartis (Primary) ; Aluminium hydroxide
- Indications Meningococcal group B infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 10 Sep 2008 Results have been reported by Novartis.
- 10 Sep 2008 Status changed from active, no longer recruiting to completed, as reported by Novartis.
- 28 Aug 2007 Status changed from initiated to in progress.